NYSE:MRK Merck & Co., Inc. (MRK) Stock Price, News & Analysis $114.36 +1.37 (+1.21%) As of 10:39 AM Eastern This is a fair market value price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsDividendEarningsFDA EventsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock About Merck & Co., Inc. Stock (NYSE:MRK) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Merck & Co., Inc. alerts:Sign Up Key Stats Today's Range$112.09▼$114.4950-Day Range$109.33▼$123.2552-Week Range$75.40▼$125.14Volume688,246 shsAverage Volume10.79 million shsMarket Capitalization$282.46 billionP/E Ratio32.16Dividend Yield2.97%Price Target$128.18Consensus RatingModerate Buy Company Overview Merck & Co., Inc. is a global biopharmaceutical company engaged in the discovery, development, manufacture and marketing of prescription medicines, vaccines, biologic therapies and animal health products. Its portfolio spans multiple therapeutic areas with a particular emphasis on oncology, vaccines and infectious disease, as well as therapies for metabolic and chronic conditions. Among its well-known products are the cancer immunotherapy Keytruda (pembrolizumab) and the human papillomavirus vaccine Gardasil; the company also markets a range of medicines and vaccines for veterinary use through Merck Animal Health. Founded in the late 19th century as the U.S. affiliate of the German Merck family business, Merck & Co. evolved into an independent American pharmaceutical company after World War I. Headquartered in Rahway, New Jersey, the company maintains a substantial global presence, selling products and conducting research and clinical development worldwide. Outside the United States and Canada it commonly operates under the MSD (Merck Sharp & Dohme) name. Customers include hospitals, health systems, public health agencies and commercial pharmacies, and the company participates in public-private partnerships and global vaccination programs. Merck places significant emphasis on research and development, investing in clinical pipelines, biologics, and vaccine technologies while engaging in collaborations with academic institutions, biotech firms and other industry partners. Its operations encompass discovery research, clinical development, regulatory affairs, manufacturing and global distribution. Executive leadership is led by Chief Executive Officer Robert M. Davis. The company’s business model combines in-house R&D with strategic alliances to advance new therapies and expand access to established products across diverse international markets.AI Generated. May Contain Errors. Read More Merck & Co., Inc. Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks94th Percentile Overall ScoreMRK MarketRank™: Merck & Co., Inc. scored higher than 94% of companies evaluated by MarketBeat, and ranked 23rd out of 856 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.4 / 5Analyst RatingModerate Buy Consensus RatingMerck & Co., Inc. has received a consensus rating of Moderate Buy. The company's average rating score is 2.68, and is based on 1 strong buy rating, 11 buy ratings, 7 hold ratings, and no sell ratings.Upside PotentialMerck & Co., Inc. has a consensus price target of $128.18, representing about 13.4% upside from its current price of $113.01.Amount of Analyst CoverageMerck & Co., Inc. has been the subject of 8 research reports in the past 90 days, demonstrating strong analyst interest in this stock.Read more about Merck & Co., Inc.'s stock forecast and price target. Earnings and Valuation2.5 / 5Proj. Earnings Growth89.53% Earnings GrowthEarnings for Merck & Co., Inc. are expected to grow by 89.53% in the coming year, from $5.16 to $9.78 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Merck & Co., Inc. is 31.83, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 44.53.Price to Earnings Ratio vs. SectorThe P/E ratio of Merck & Co., Inc. is 31.83, which means that it is trading at a more expensive P/E ratio than the Medical sector average P/E ratio of about 20.82.Price to Earnings Growth RatioMerck & Co., Inc. has a PEG Ratio of 2.57. PEG Ratios above 1 indicate that a company could be overvalued.Price to Book Value per Share RatioMerck & Co., Inc. has a P/B Ratio of 6.08. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.Read more about Merck & Co., Inc.'s valuation and earnings. Short Interest4.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted1.06% of the float of Merck & Co., Inc. has been sold short.Short Interest Ratio / Days to CoverMerck & Co., Inc. has a short interest ratio ("days to cover") of 2.55, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Merck & Co., Inc. has recently decreased by 4.69%, indicating that investor sentiment is improving. Dividend3.3 / 5Dividend StrengthStrong Dividend YieldMerck & Co., Inc. pays a meaningful dividend of 2.98%, higher than the bottom 25% of all stocks that pay dividends.Dividend GrowthMerck & Co., Inc. has been increasing its dividend for 14 years.Dividend CoverageThe dividend payout ratio of Merck & Co., Inc. is 95.77%. Payout ratios above 75% are not desirable because they may not be sustainable.Dividend SustainabilityBased on earnings estimates, Merck & Co., Inc. will have a dividend payout ratio of 34.76% next year. This indicates that Merck & Co., Inc. will be able to sustain or increase its dividend.Read more about Merck & Co., Inc.'s dividend. News and Social Media3.8 / 5News Sentiment1.03 News SentimentMerck & Co., Inc. has a news sentiment score of 1.03. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.38 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 34 news articles for Merck & Co., Inc. this week, compared to 13 articles on an average week.Search InterestOnly 82 people have searched for MRK on MarketBeat in the last 30 days. This is a decrease of -1% compared to the previous 30 days.MarketBeat Follows47 people have added Merck & Co., Inc. to their MarketBeat watchlist in the last 30 days. This is an increase of 135% compared to the previous 30 days. Company Ownership0.7 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Merck & Co., Inc. insiders have not sold or bought any company stock.Percentage Held by Insiders0.17% of the stock of Merck & Co., Inc. is held by insiders.Percentage Held by Institutions76.07% of the stock of Merck & Co., Inc. is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Merck & Co., Inc.'s insider trading history. Receive MRK Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Merck & Co., Inc. and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. MRK Stock News HeadlinesTop Dividend Stocks To Consider In May 20261 hour ago | finance.yahoo.comHow Eisai (TSE:4523) Is Reframing Its Story With A Tweaked Fair Value Outlook1 hour ago | finance.yahoo.comIran's New Leader Just Said Something That Should Terrify Every AmericanIran's Supreme Leader has declared the Strait of Hormuz closed as leverage against the U.S. - and with 40% of the world's oil passing through that corridor, crude has already crossed $100 per barrel. History shows gold surged 571% during the 1973 oil crisis and 425% in 1979. Today, the U.S. holds 8,133 tonnes of gold valued on the books at $42.22 per ounce - while gold trades above $5,000. American Alternative Assets has released The Great Gold Reset report detailing what this gap could mean for investors.May 21 at 1:00 AM | American Alternative (Ad)Oligometastatic Disease Market Analysis Report 2026-2036, Profiles of Leading Players - Dompe Farmaceutici, Bausch Health, Merck, Pfizer, and Glenmark Pharmaceuticals1 hour ago | finance.yahoo.comSome Investors May Be Willing To Look Past Merck KGaA's (ETR:MRK) Soft EarningsMay 21 at 4:20 AM | finance.yahoo.com2 reasons to watch MRK and 1 to stay cautiousMay 20 at 5:38 PM | msn.comWhy Regeneron (REGN) Shares Are Trading Lower TodayMay 20 at 12:32 PM | finance.yahoo.comNational Advertising Review Board Refers Merck Animal Health to FTC and FDA for Bravecto Quantum Dosing ClaimsMay 20 at 11:00 AM | globenewswire.comSee More Headlines MRK Stock Analysis - Frequently Asked Questions How have MRK shares performed this year? Merck & Co., Inc.'s stock was trading at $105.20 at the beginning of 2026. Since then, MRK shares have increased by 7.4% and is now trading at $113.0130. How were Merck & Co., Inc.'s earnings last quarter? Merck & Co., Inc. (NYSE:MRK) announced its quarterly earnings results on Thursday, April, 30th. The company reported ($1.28) earnings per share for the quarter, beating the consensus estimate of ($1.47) by $0.19. The business's quarterly revenue was up 4.9% on a year-over-year basis. Read the conference call transcript. Is Merck & Co., Inc. buying back stock? Merck & Co., Inc.'s Board of Directors approved a stock buyback program on Tuesday, January 28th 2025, which authorizes the company to repurchase $10,000,000,000 in outstanding shares, according to EventVestor. This means that the company could reacquire up to 4.1% of its shares through open market purchases. Shares buyback programs are typically a sign that the company's board believes its shares are undervalued. Who are Merck & Co., Inc.'s major shareholders? Top institutional shareholders of Merck & Co., Inc. include Bank of America Corp DE (1.25%), Bank of New York Mellon Corp (0.76%), Dimensional Fund Advisors LP (0.63%) and Amundi (0.56%). Insiders that own company stock include Robert M Davis, Richard R Deluca, Dean Y Li, Caroline Litchfield, Chirfi Guindo, Jennifer Zachary, David Michael Williams, Steven Mizell, Johannes Jacobus Oosthuizen, Joseph Romanelli, Dalton E Smart III, Cristal N Downing and Inge G Thulin. View institutional ownership trends. How do I buy shares of Merck & Co., Inc.? Shares of MRK stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Merck & Co., Inc. own? Based on aggregate information from My MarketBeat watchlists, some other companies that Merck & Co., Inc. investors own include Chevron (CVX), Salesforce (CRM), Bristol Myers Squibb (BMY), Comcast (CMCSA), Johnson & Johnson (JNJ), AbbVie (ABBV) and Home Depot (HD). Company Calendar Record date for 4/7 Dividend3/16/2026Ex-Dividend for 4/7 Dividend3/16/2026Dividend Payable4/07/2026Last Earnings4/30/2026Today5/21/2026AGM 20265/26/2026Investor update6/01/2026Next Earnings (Estimated)8/04/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Green Zone (2w+) 1-Year History May 25 Aug 25 Nov 25 Feb 26 May 26 For the last 2 weeks, MRK's financial health has been in the Green zone, according to TradeSmith. Industry, Sector and Symbol Stock ExchangeNYSE SectorMedical Industry Large Cap Pharma Sub-IndustryPharmaceuticals Current SymbolNYSE:MRK CIK310158 Webwww.merck.com Phone(908) 740-4000Fax908-735-1253Employees75,000Year Founded1891Price Target and Rating Average Price Target for Merck & Co., Inc.$128.18 High Price Target$150.00 Low Price Target$90.00 Potential Upside/Downside+12.9%Consensus RatingModerate Buy Rating Score (0-4)2.68 Research Coverage19 Analysts Profitability EPS (Trailing Twelve Months)$3.55 Trailing P/E Ratio31.86 Forward P/E Ratio22.00 P/E Growth2.57Net Income$18.25 billion Net Margins13.59% Pretax Margin17.68% Return on Equity27.55% Return on Assets10.73% Debt Debt-to-Equity Ratio1.02 Current Ratio1.30 Quick Ratio1.06 Sales & Book Value Annual Sales$65.01 billion Price / Sales4.31 Cash Flow$11.35 per share Price / Cash Flow10.00 Book Value$18.60 per share Price / Book6.10Miscellaneous Outstanding Shares2,469,820,000Free Float2,465,625,000Market Cap$280.34 billion OptionableOptionable Beta0.18 Social Links 7 Stocks That Could Be Bigger Than Tesla, Nvidia, and GoogleLooking for the next FAANG stock before everyone has heard about it? Click the link to see which stocks MarketBeat analysts think might become the next trillion dollar tech company.Get This Free Report This page (NYSE:MRK) was last updated on 5/21/2026 by MarketBeat.com Staff. From Our PartnersSpaceX eyes a 1.75 trillion valuation - here's what to knowElon Musk's team has quietly filed confidential paperwork with the SEC for what Bloomberg estimates could be a...Brownstone Research | SponsoredIran's New Leader Just Said Something That Should Terrify Every AmericanIran's Supreme Leader has declared the Strait of Hormuz closed as leverage against the U.S. - and with 40% of ...American Alternative | Sponsored$30 stock to buy before Starlink goes public (WATCH NOW!)In the next 3 minutes… James Altucher – legendary investor and venture capitalist… And someone who’s kno...Paradigm Press | SponsoredTrump's gold order: the announcement they won't put on the front pageOn August 15, 1971, Nixon interrupted prime-time television and ended the gold standard in 15 minutes - no deb...Reagan Gold Group | SponsoredMy feud with Zohran MamdaniEmmy-winning analyst releases his next big story Whitney Tilson shocked the nation on 60 Minutes when he ac...Stansberry Research | SponsoredIran War Shock: What I Was Told In That Private MeetingYou’re Being LIED To About The Iran War Forget EVERYTHING you’ve heard about the Iran war. Especially th...Banyan Hill Publishing | SponsoredWhy this tiny stock may move before the SpaceX IPO dropsThe projected SpaceX and xAI S-1 filing hits the SEC on June 1st - and analyst Dylan Jovine says $1.75 trillio...Behind the Markets | SponsoredYour book attachedBill Poulos is giving away his 'Safe Trade Options Formula' book for free - but only for a limited time throug...Profits Run | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Merck & Co., Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Merck & Co., Inc. With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
